CNBC’s Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that’s been weighed down by ...

Abbott Laboratories and Reckitt Benckiser shares surged on Friday after a Missouri court ruled in the two companies’ favor in a dispute over claims their specialist infant formulas had caused a ...

On Monday, Barclays maintained an Overweight rating on Abbott Labs (NYSE:ABT) shares and increased the price target to $149 from $143. The adjustment follows a favorable verdict for Abbott in a ...

Nov 1 (Reuters) - Abbott Laboratories (ABT.N), opens new tab shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over ...

A jury found Abbott Laboratories and Mead Johnson, owned by U.K.-based Reckitt Benckiser, not responsible for a young boy's intestinal disease, the result of a lawsuit that alleged the companies ...

CNBC's Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that's been weighed down by ongoing litigation for several months. Abbott was cleared Thursday night of ...

A Missouri jury found Abbott Laboratories (ABT) and a unit of Reckitt Benckiser (RBGLY) not responsible for an infant death originally claimed to be tied to the company's baby formulas.

Abbott Laboratories and a unit of Reckitt Benckiser Group Plc were cleared by a jury over claims they hid risks their premature-infant formulas can cause a bowel disease that severely sickened a ...